Back to Screener

Fresenius Medical Care AG (FMS)

Price$22.03
Value ScoreA
Growth ScoreD
Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-15.30%
Price vs S&P 500 (4W)2.45%
VGM Score55.10
Market Capitalization$11.60B
P/E Ratio (Annual)10.25x
Indicated Dividend Yield (Annual)3.95%

All Metrics

P/CF (Annual)3.74x
Book Value / Share (Quarterly)$56.70
P/TBV (Annual)0.98x
Indicated Dividend (Annual)$1.72
Revenue Growth (3Y)0.39%
Cash Flow / Share (Quarterly)$7.56
Payout Ratio (TTM)187.56%
Price vs S&P 500 (YTD)-13.69%
Gross Margin (TTM)25.95%
Net Profit Margin (TTM)4.88%
EPS (TTM)$3.79
10-Day Avg Trading Volume0.96M
EPS Excl Extra (TTM)$3.79
Revenue Growth (5Y)1.91%
EPS (Annual)$3.89
Dividend / Share (Annual)$1.71
ROI (Annual)4.06%
Gross Margin (Annual)25.62%
Net Profit Margin (5Y Avg)3.86%
Cash / Share (Quarterly)$6.95
P/E Basic Excl Extra (TTM)10.62x
Revenue Growth QoQ (YoY)-5.51%
EPS Growth (5Y)-3.23%
P/E Normalized (Annual)10.25x
ROA (Last FY)3.16%
Revenue Growth TTM (YoY)-0.69%
EBITD / Share (TTM)$13.52
ROE (5Y Avg)5.43%
Operating Margin (TTM)9.20%
Cash Flow / Share (Annual)$7.22
P/B Ratio0.76x
P/B Ratio (Quarterly)0.85x
Net Income / Employee (Annual)$10,293
EV / Revenue (TTM)1.02x
Net Interest Coverage (TTM)6.95x
ROA (TTM)3.03%
EPS Growth QoQ (YoY)-17.15%
EV / EBITDA (TTM)5.91x
EPS Incl Extra (Annual)$3.89
Current Ratio (Annual)1.26x
Quick Ratio (Quarterly)0.86x
3-Month Avg Trading Volume0.88M
52-Week Price Return-23.79%
EV / Free Cash Flow (Annual)11.37x
P/E Incl Extra (TTM)10.62x
Revenue / Employee (TTM)$204,121
Tangible BV / Share (Quarterly)$51.32
P/S Ratio (Annual)0.51x
Asset Turnover (Annual)0.63x
52-Week High$50.94
Operating Margin (5Y Avg)8.37%
EPS Excl Extra (Annual)$3.89
CapEx CAGR (5Y)-2.89%
Tangible BV CAGR (5Y)4.16%
26-Week Price Return-7.38%
Quick Ratio (Annual)0.90x
13-Week Price Return-2.48%
Total Debt / Equity (Annual)0.81x
Current Ratio (Quarterly)1.20x
Enterprise Value$22.92B
Revenue / Share Growth (5Y)2.11%
Asset Turnover (TTM)0.62x
Book Value / Share Growth (5Y)4.47%
Revenue / Employee (Annual)$206,897
Inventory Turnover (Annual)6.94x
Pretax Margin (Annual)7.70%
Cash / Share (Annual)$7.67
3-Month Return Std Dev32.40%
Gross Margin (5Y Avg)25.57%
Net Income / Employee (TTM)$9,946
EBITDA CAGR (5Y)7.58%
EBITDA Interim CAGR (5Y)9.51%
ROE (Last FY)7.35%
Net Interest Coverage (Annual)8.57x
EPS Basic Excl Extra (Annual)$3.89
P/FCF (TTM)5.68x
Receivables Turnover (TTM)5.42x
EV / Free Cash Flow (TTM)11.23x
Total Debt / Equity (Quarterly)0.83x
EPS Incl Extra (TTM)$3.79
Receivables Turnover (Annual)6.03x
ROI (TTM)3.93%
Dividend Growth Rate (5Y)4.43%
P/S Ratio (TTM)0.52x
Pretax Margin (5Y Avg)6.74%
Revenue / Share (Annual)$77.95
Tangible BV / Share (Annual)$49.92
Forward P/E9.02x
Free OCF CAGR (5Y)-11.14%
Price vs S&P 500 (52W)-48.16%
P/E Ratio (TTM)10.62x
EPS Growth TTM (YoY)55.68%
Year-to-Date Return-6.33%
5-Day Price Return4.89%
EPS Normalized (Annual)$3.89
ROA (5Y Avg)2.19%
Net Profit Margin (Annual)4.98%
Month-to-Date Return2.66%
Cash Flow / Share (TTM)$9.02
EBITD / Share (Annual)$13.22
EPS Growth (3Y)13.53%
Operating Margin (Annual)9.31%
LT Debt / Equity (Annual)0.43x
P/CF (TTM)3.65x
ROI (5Y Avg)2.86%
P/E Excl Extra (TTM)10.62x
LT Debt / Equity (Quarterly)0.43x
EPS Basic Excl Extra (TTM)$3.79
P/TBV (Quarterly)0.94x
Payout Ratio (Annual)43.19%
P/B Ratio (Annual)0.89x
Dividend / Share (TTM)$1.71
Inventory Turnover (TTM)6.54x
Pretax Margin (TTM)7.59%
Book Value / Share (Annual)$55.11
Price vs S&P 500 (13W)-10.73%
Net Margin Growth (5Y)-5.25%
Dividend Yield (TTM)4.21%
Beta0.36x
P/FCF (Annual)5.75x
Revenue / Share (TTM)$81.34
ROE (TTM)7.16%
52-Week Low$34.57
vGradeA
gGradeD
mGradeC
vgmGradeC
Show chart for

Analyst Recommendations

Mar 2026
Apr 2026
May 2026
Jun 2026
3.30
3.30
3.30
3.31

About

Fresenius Medical Care is the world's largest dialysis provider, operating approximately 3,600 clinics treating nearly 300,000 patients globally. As the only fully integrated dialysis business, it controls roughly 35% of the global dialysis products market through supplies of machines, dialyzers, and concentrates. The company generates approximately 75% of revenue from services and 25% from dialysis products, creating a diversified business model with competitive advantages in both treatment delivery and product supply.